For the first quarter of 2026, analysts anticipate Insmed to report consensus revenue of $114.8 million and an EPS loss of -$0.92, with the current stock price of $74.85 trading significantly below the average analyst price target of $92.40. Investors are primarily focused on the net sales performance of ARIKAYCE and updates regarding the commercialization timeline for brensocatib.
Following the positive Phase 3 ASPEN trial results, the market is looking for evidence of sustained growth in the core NTM franchise to offset increased R&D spending. Analysts will also be scanning the report for updates on the TPIP clinical program and the company’s current cash runway as it transitions into a multi-product commercial-stage entity.